News

Kioxia Unveils Revolutionary OCTRAM Technology for DRAM

Kioxia Unveils Revolutionary OCTRAM Technology for DRAM

Kioxia's Groundbreaking OCTRAM Technology

Kioxia Corporation, a leading name in memory solutions, recently made an exciting announcement regarding their innovative OCTRAM (Oxide-Semiconductor Channel Transistor DRAM). This new DRAM technology, represented in a unique 4F2 configuration, features an oxide-semiconductor transistor known for its remarkably high ON current and extremely low OFF current. This advancement promises the realization of low power DRAM, showcasing the ultra-low leakage properties of InGaZnO.

Transformative Benefits of OCTRAM Technology

This technological breakthrough delivers several benefits. Notably, it may significantly reduce power consumption across diverse applications, including AI technologies, emerging post-5G communication systems, and various Internet of Things (IoT) devices. Jointly developed by Kioxia Corporation and Nanya Technology, OCTRAM is positioned to be a game-changer in the realm of memory technology.

OCTRAM Design Features

The design of the OCTRAM is particularly noteworthy. It incorporates a cylinder-shaped InGaZnO vertical transistor as its cell transistor. This design shift allows adaptation to the 4F2 DRAM format, offering enhanced memory density when compared to traditional silicon-based DRAM, which typically operates on a 6F2 format.

Device Optimization

Performance metrics for the InGaZnO vertical transistor are impressive, achieving a high ON current exceeding 15?A/cell and an ultra-low OFF current dipping below 1aA/cell. These specifications are the result of meticulous device and process optimization. Another essential feature of the OCTRAM structure is the integration of the InGaZnO vertical transistor atop a high aspect ratio capacitor, allowing for improved performance driven by a capacitor-first process.

Future Applications and Implications

The implications of the OCTRAM technology extend significantly into future applications. With lower power consumption, it paves the way for advancements in multiple sectors, such as AI-driven systems, 5G technology, IoT products, and more. As these fields continue to evolve, Kioxia's OCTRAM aims to meet the growing demand for high-performance, energy-efficient memory solutions.

About Kioxia Corporation

Kioxia, renowned in the memory solutions space, is committed to innovative development, production, and sales of flash memory and solid-state drives (SSDs). The company's legacy traces back to April 2017 when its predecessor, Toshiba Memory, spun off from Toshiba Corporation, which originally created NAND flash memory in 1987. By offering products designed for high-density applications, such as advanced smartphones, PCs, and data centers, Kioxia actively contributes to the development of memory technologies that align with modern digital needs.

Frequently Asked Questions

What is OCTRAM technology?

OCTRAM (Oxide-Semiconductor Channel Transistor DRAM) is a new type of DRAM developed by Kioxia that boasts high ON and low OFF currents to achieve energy efficiency.

What advantages does OCTRAM offer?

This technology aims to reduce power consumption significantly across applications such as AI, post-5G systems, and IoT devices.

How does OCTRAM compare to traditional DRAM?

OCTRAM employs a 4F2 structure for better memory density versus the conventional 6F2 DRAM technology.

Who collaborated on the development of OCTRAM?

Kioxia Corporation collaborated with Nanya Technology in developing this innovative memory solution.

What future applications can benefit from OCTRAM?

OCTRAM technology is poised to enhance advancements in AI, telecommunications, and IoT ecosystems.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading